<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104763</url>
  </required_header>
  <id_info>
    <org_study_id>9261_2019</org_study_id>
    <nct_id>NCT04104763</nct_id>
  </id_info>
  <brief_title>Osteofibrous Dysplasia (Kempson-Campanacci's Disease)</brief_title>
  <acronym>DOFOL</acronym>
  <official_title>Osteofibrous Dysplasia (Kempson-Campanacci's Disease): Long Term Follow-up Study on Natural History, Results of Treatment and Relationship With Adamantinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to obtain long term follow-up in patients with osteofibrous
      dysplasia, to assess natural history of the disease, late results of treatment and in
      particular the potential and risk of progression to adamantinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Osteofibrous Dysplasia (Kempson-Campanacci's disease): Long Term Follow-up Study on Natural History, Results of Treatment and Relationship with Adamantinoma</measure>
    <time_frame>BASELINE</time_frame>
    <description>We will retrieve from the database of the Rizzoli institute all the cases with a histological diagnosis of Ewing sarcoma from 01 Jan 1943 to 31 Dic 2011.
We aspect to find approximately 55 cases. We will review all the medical records, radiological imaging, and histological data of these cases.</description>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Osteofibrous Dysplasia</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>study of osteofibrous dysplasia features</intervention_name>
    <description>obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is single institution cases series review of histological and clinical data
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients treated at Rizzoli Institute from 01 Jan 1943 to 31 Dic 2011

          -  Diagnosis of osteofibrous dysplasia pathologically confirmed

          -  Written informed consent prior to any study-specific analysis and/or data collection

        Exclusion Criteria:

          -  Patients with histological diagnosis different from osteofibrous dysplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ALBERTO RIGHI, MD PhD</last_name>
    <phone>+39-051-636</phone>
    <phone_ext>6665</phone_ext>
    <email>alberto.righi@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Pathology of IRCCS Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Righi, MD</last_name>
      <phone>+39051.63.66</phone>
      <phone_ext>665</phone_ext>
      <email>alberto.righi@ior.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Benassi MS, Campanacci L, Gamberi G, Ferrari C, Picci P, Sangiorgi L, Campanacci M. Cytokeratin expression and distribution in adamantinoma of the long bones and osteofibrous dysplasia of tibia and fibula. An immunohistochemical study correlated to histogenesis. Histopathology. 1994 Jul;25(1):71-6.</citation>
    <PMID>7525449</PMID>
  </results_reference>
  <results_reference>
    <citation>Scholfield DW, Sadozai Z, Ghali C, Sumathi V, Douis H, Gaston L, Grimer RJ, Jeys L. Does osteofibrous dysplasia progress to adamantinoma and how should they be treated? Bone Joint J. 2017 Mar;99-B(3):409-416. doi: 10.1302/0301-620X.99B3.38050.</citation>
    <PMID>28249983</PMID>
  </results_reference>
  <results_reference>
    <citation>Gleason BC, Liegl-Atzwanger B, Kozakewich HP, Connolly S, Gebhardt MC, Fletcher JA, Perez-Atayde AR. Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinicopathologic reappraisal. Am J Surg Pathol. 2008 Mar;32(3):363-76. doi: 10.1097/PAS.0b013e318150d53e.</citation>
    <PMID>18300815</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Alberto Righi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Developmental</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04104763/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

